Synapses between primary afferents and dorsal horn neurons are key sites for pain modulation, because they determine the intensity of nociceptive signals entering the spinal cord. NMDA receptors (NMDARs) are expressed by primary afferents and are present in their central and peripheral terminals. Although little is known about their role in pain, NMDARs in the central terminals may be involved in long-term potentiation of these synapses, thus contributing to central sensitization. This project is based on our results indicating that these NMDARs are normally in a non-functional state and become functional during the induction of chronic pain. This resolves an ongoing controversy: an initial report found that intrathecal injections of NMDA to rats induced substance P release from primary afferents, but it could not be replicated by later studies including our own. We now find that intrathecal NMDA preceded by brain-derived neurotrophic factor (BDNF) elicited a substantial amount of substance P release. Co-injection of a Src family kinase (SFK) inhibitor with BDNF suppressed the effect of NMDA, suggesting that BDNF induces the SFK phosphorylation of NMDARs. In addition to BDNF, ephrinB2 also appears to enable NMDA-induced substance P release. Importantly, we found that in a nerve injury model these NMDARs become functional for 3 days, consistent with evidence that nerve injury induces BDNF release from activated microglia and activates the ephrinB/EphB receptor system. Accordingly, this project will test the following hypotheses: 1) To be functional, NMDARs in primary afferents require Tyr-phosphorylation of their NR2B subunit, which is determined by the balance of activities of SFKs and protein tyrosine phosphatases, 2) SFK phosphorylation of NMDARs in primary afferents is initiated by BDNF and ephrins, and 3) NMDARs in primary afferent terminals are non-functional (i.e. not phosphorylated) under normal conditions and become phosphorylated in some chronic pain states.
The Specific Aims are: 1) study the role of SFK phosphorylation in modulating NMDARs in primary afferents, 2) identify the signals upstream of SFK phosphorylation of these NMDARs, and 3) investigate the involvement of NMDARs in primary afferents in chronic pain. The approach includes the use of two strains of transgenic mice with selective knockdown of NMDARs in dorsal root ganglia (DRG) to determine whether the NMDARs that induce substance P release (measured as neurokinin 1 receptor internalization) and contribute to neuropathic and visceral pain are located in primary afferents. The SFK that phosphorylates these NMDARs will be identified by selective small interference RNA (siRNA) knockdown in DRG of each of the five neuronal SFKs. Western blots of DRG extracts will serve to measure tyrosine phosphorylation of the NR2B subunit after treatment with BDNF and ephrinB. Patch-clamp recordings in cultured DRG neurons will study changes in NMDARs currents after adding BDNF and ephrinB. Using rodent models, we will test the predictions that neuropathic and visceral pain increase NMDA-induced SP release, and decrease after selective knockdown of NMDARs in primary afferents.

Public Health Relevance

Neuropathic pain consists in spontaneous pain or increases in pain intensity originating with lesions in nerves or the central nervous system, and affects a large sector of the population (two million cases in the United States). Inflammation pain, irritable bowel syndrome and other forms of chronic pain are also significant health concerns. This project will study changes that occur during chronic pain in the mechanisms by which pain fibers deliver their messages to the spinal cord, focusing on the NMDA receptors and the signaling molecules that modulate their activity.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA033059-04
Application #
8841333
Study Section
Special Emphasis Panel (ZRG1-IFCN-N (02))
Program Officer
Sorensen, Roger
Project Start
2012-07-01
Project End
2017-04-30
Budget Start
2015-05-01
Budget End
2016-04-30
Support Year
4
Fiscal Year
2015
Total Cost
$273,042
Indirect Cost
$56,342
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Chen, Wenling; Taché, Yvette; Marvizón, Juan Carlos (2018) Corticotropin-Releasing Factor in the Brain and Blocking Spinal Descending Signals Induce Hyperalgesia in the Latent Sensitization Model of Chronic Pain. Neuroscience 381:149-158
Severino, Amie; Chen, Wenling; Hakimian, Joshua K et al. (2018) Mu-opioid receptors in nociceptive afferents produce a sustained suppression of hyperalgesia in chronic pain. Pain 159:1607-1620
Chen, Wenling; Ennes, Helena S; McRoberts, James A et al. (2018) Mechanisms of ?-opioid receptor inhibition of NMDA receptor-induced substance P release in the rat spinal cord. Neuropharmacology 128:255-268
Walwyn, Wendy M; Chen, Wenling; Kim, Hyeyoung et al. (2016) Sustained Suppression of Hyperalgesia during Latent Sensitization by ?-, ?-, and ?-opioid receptors and ?2A Adrenergic Receptors: Role of Constitutive Activity. J Neurosci 36:204-21
Marvizon, Juan Carlos; Walwyn, Wendy; Minasyan, Ani et al. (2015) Latent sensitization: a model for stress-sensitive chronic pain. Curr Protoc Neurosci 71:9.50.1-14
Chen, Wenling; Walwyn, Wendy; Ennes, Helena S et al. (2014) BDNF released during neuropathic pain potentiates NMDA receptors in primary afferent terminals. Eur J Neurosci 39:1439-54
Chen, W; McRoberts, J A; Marvizón, J C G (2014) ?-Opioid receptor inhibition of substance P release from primary afferents disappears in neuropathic pain but not inflammatory pain. Neuroscience 267:67-82
Taylor, B K; Fu, W; Kuphal, K E et al. (2014) Inflammation enhances Y1 receptor signaling, neuropeptide Y-mediated inhibition of hyperalgesia, and substance P release from primary afferent neurons. Neuroscience 256:178-94